Citadel Advisors
ZVRA icon

Citadel Advisors’s Zevra Therapeutics ZVRA Stock Holding History

Citadel Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.84M Sell
626,699
-216,155
-26% -$1.95M ﹤0.01% 4088
2025
Q4 		$7.55M Buy
842,854
+651,058
+339% +$6.16M ﹤0.01% 3649
2025
Q3 		$1.82M Buy
191,796
+77,529
+68% +$778K ﹤0.01% 6262
2025
Q2 		$1.01M Sell
114,267
-134,565
-54% -$1.09M ﹤0.01% 7067
2025
Q1 		$1.86M Buy
248,832
+246,343
+9,897% +$1.96M ﹤0.01% 5661
2024
Q4 		$20.8K Sell
2,489
-65,420
-96% -$558K ﹤0.01% 13163
2024
Q3 		$471K Sell
67,909
-37,329
-35% -$253K ﹤0.01% 8388
2024
Q2 		$516K Buy
105,238
+104,913
+32,281% +$497K ﹤0.01% 7977
2024
Q1 		$1.89K Sell
325
-334,452
-100% -$2.06M ﹤0.01% 14075
2023
Q4 		$2.19M Buy
334,777
+167,107
+100% +$782K ﹤0.01% 5200
2023
Q3 		$808K Buy
167,670
+139,229
+490% +$695K ﹤0.01% 7015
2023
Q2 		$145K Sell
28,441
-2,745
-9% -$14.8K ﹤0.01% 10390
2023
Q1 		$172K Sell
31,186
-77,674
-71% -$411K ﹤0.01% 10428
2022
Q4 		$500K Buy
+108,860
New +$553K ﹤0.01% 8238
2022
Q1 		– Sell
-23,813
Closed -$152K – 14740
2021
Q4 		$207K Sell
23,813
-5,165
-18% -$46.1K ﹤0.01% 11781
2021
Q3 		$270K Buy
28,978
+812
+3% +$8.19K ﹤0.01% 11300
2021
Q2 		$361K Sell
28,166
-129,305
-82% -$1.39M ﹤0.01% 10822
2021
Q1 		$1.45M Buy
+157,471
New +$1.38M ﹤0.01% 7194
2020
Q1 		– Sell
-2,606
Closed -$16K – 10298
2019
Q4 		$16K Buy
+2,606
New +$20.7K ﹤0.01% 8968

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Citadel Advisors's ZVRA Position: Q1 2026 in Review

Citadel Advisors reduced its Zevra Therapeutics (ZVRA) stake by 26% in Q1 2026, selling an estimated $1.95M and leaving 626,699 shares worth $5.84M. The position accounts for ﹤0.01% of the portfolio, ranked #4088.

Citadel Advisors first reported a position in ZVRA in Q4 2019 and has held it in 19 quarters since. The position peaked at $7.55M in Q4 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Citadel Advisors held 626,699 shares of Zevra Therapeutics worth $5.84M as of Q1 2026.
  • Citadel Advisors sold 216,155 Zevra Therapeutics shares in Q1 2026, an estimated $1.95M.
  • Zevra Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4088 holding.
  • Citadel Advisors first reported a position in Zevra Therapeutics in Q4 2019 and has held it in 19 quarters since.
  • Citadel Advisors's Zevra Therapeutics position peaked at $7.55M in Q4 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.